{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:43:26Z","timestamp":1762253006636},"reference-count":117,"publisher":"Bentham Science Publishers Ltd.","issue":"28","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,10,25]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Acute Myeloid Leukaemia (AML) is the neoplastic transformation of Hematopoietic Stem Cells (HSC) and relapsed disease is a major challenge in the treatment. Despite technological advances in the field of medicine and our heightened knowledge regarding the pathogenesis of AML, the initial therapy of \u201c7+3\u201d Cytarabine and Daunorubicin has remained mainly unchanged since 1973. AML is a disease of the elderly, and increased morbidity in this patient group does not allow the full use of the treatment and drug-resistant relapse is common.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>Nanocarriers are drug-delivery systems that can be used to transport drugs to the bone marrow and target Leukemic Stem Cells (LSC), conferring less side-effects compared to the free-drug alternative. Nanocarriers also can be used to favour the transport of drugs that otherwise would not have been used clinically due to toxicity and poor efficacy. Liposomes are a type of nanocarrier that can be used as a dedicated drug delivery system, which can also have active ligands on the surface in order to interact with antigens on the target cells or tissues. In addition to using small molecules, it is possible to attach antibodies to the liposome surface, generating so-called immunoliposomes. By using immunoliposomes as a drug-delivery system, it is possible to minimize the toxic side effects caused by the chemotherapeutic drug on healthy organs, and at the same time direct the drugs towards the remaining AML blasts and stem cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>This article aims to explore the possibilities of using immunoliposomes as a drug carrier in AML therapy. Emphasis will be on possible target molecules on the AML cells, leukaemic stem cells, as well as bone marrow constituents relevant to AML therapy. Further, some conditions and precautions that must be met for immunoliposomes to be used in AML therapy will be discussed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867326666190517114450","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T11:06:31Z","timestamp":1558091191000},"page":"5278-5292","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles"],"prefix":"10.2174","volume":"26","author":[{"given":"Aditi","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai Norevik","family":"Myklebust","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Marie Vie","family":"Furevik","sequence":"additional","affiliation":[{"name":"Hospital pharmacies enterprise, Western Norway, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragnhild","family":"Haugse","sequence":"additional","affiliation":[{"name":"Hospital pharmacies enterprise, Western Norway, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Herfindal","sequence":"additional","affiliation":[{"name":"Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"Estey E.","year":"2006","unstructured":"Estey E.; D\u00f6hner H.; Acute myeloid leukaemia. Lancet 2006,368(9550),1894-1907","journal-title":"Lancet"},{"key":"ref=2","author":"Howlader N.","year":"2016","unstructured":"Howlader N.; Krapcho M.; Miller D.; Bishop K.; Altekruse S.F.; Kosary C.L.; Yu M.; Ruhl J.; Tatalovich Z.; SEER cancer statistics reveiw, 1975-2013 2016","journal-title":"SEER cancer statistics reveiw, 1975-2013"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2174\/1389201016666150907113653","volume":"17","author":"Forthun R.B.","year":"2016","unstructured":"Forthun R.B.; Hinrichs C.; Dowling T.H.; Bruserud \u00d8.; Selheim F.; The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia. Curr Pharm Biotechnol 2016,17(1),6-19","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clml.2014.08.006","volume":"15","author":"Kadia T.M.","year":"2015","unstructured":"Kadia T.M.; Ravandi F.; O\u2019Brien S.; Cortes J.; Kantarjian H.M.; Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2015,15(3),139-151","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","volume":"127","author":"Stein E.M.","year":"2016","unstructured":"Stein E.M.; Tallman M.S.; Emerging therapeutic drugs for AML. Blood 2016,127(1),71-78","journal-title":"Blood"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"Burnett A.","year":"2011","unstructured":"Burnett A.; Wetzler M.; L\u00f6wenberg B.; Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011,29(5),487-494","journal-title":"J Clin Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11864-011-0162-4","volume":"12","author":"Motyckova G.","year":"2011","unstructured":"Motyckova G.; Stone R.M.; Treatment of elderly acute myeloid leukemia patients. Curr Treat Options Oncol 2011,12(4),341-353","journal-title":"Curr Treat Options Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1586\/17474086.2014.965140","volume":"7","author":"Lehrnbecher T.","year":"2014","unstructured":"Lehrnbecher T.; Sung L.; Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia. Expert Rev Hematol 2014,7(6),819-830","journal-title":"Expert Rev Hematol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3727\/096504014X14146137738547","volume":"22","author":"Ross K.","year":"2015","unstructured":"Ross K.; Gillespie-Twardy A.L.; Agha M.; Raptis A.; Hou J.Z.; Farah R.; Redner R.L.; Im A.; Duggal S.; Ding F.; Lin Y.; Boyiadzis M.; Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia. Oncol Res 2015,22(2),85-92","journal-title":"Oncol Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bcmd.2012.10.005","volume":"50","author":"Lichtman M.A.","year":"2013","unstructured":"Lichtman M.A.; A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells Mol Dis 2013,50(2),119-130","journal-title":"Blood Cells Mol Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","volume":"129","author":"Levis M.","year":"2017","unstructured":"Levis M.; Midostaurin approved for FLT3-mutated AML. Blood 2017,129(26),3403-3406","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-3-319-91439-8_10","volume":"212","author":"Schlenk R.F.","year":"2018","unstructured":"Schlenk R.F.; Kayser S.; Midostaurin: A multiple tyrosine kinases inhibitor in acute myeloid leukemia and systemic mastocytosis. Recent Results Cancer Res 2018,212,199-214","journal-title":"Recent Results Cancer Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","volume":"381","author":"Ferrara F.","year":"2013","unstructured":"Ferrara F.; Schiffer C.A.; Acute myeloid leukaemia in adults. Lancet 2013,381(9865),484-495","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3892\/or.10.4.915","volume":"10","author":"Bieker R.","year":"2003","unstructured":"Bieker R.; Lerchenm\u00fcller C.; Wehmeyer J.; Serve H.L.; Mesters R.M.; B\u00fcchner T.; Berdel W.E.; Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep 2003,10(4),915-920","journal-title":"Oncol Rep"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00277-002-0509-9","volume":"81","author":"Russo D.","year":"2002","unstructured":"Russo D.; Piccaluga P.P.; Michieli M.; Michelutti T.; Visani G.; Gugliotta L.; Bonini A.; Pierri I.; Gobbi M.; Tiribelli M.; Fanin R.; Piccolrovazzi S.; Baccarani M.; Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Hematol 2002,81(8),462-466","journal-title":"Ann Hematol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","volume":"25","author":"Krauss A.C.","year":"2019","unstructured":"Krauss A.C.; Gao X.; Li L.; Manning M.L.; Patel P.; Fu W.; Janoria K.G.; Gieser G.; Bateman D.A.; Przepiorka D.; Shen Y.L.; Shord S.S.; Sheth C.M.; Banerjee A.; Liu J.; Goldberg K.B.; Farrell A.T.; Blumenthal G.M.; Pazdur R.; FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res 2019,25(9),2685-2690","journal-title":"Clin Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1389201016666150817095045","volume":"17","author":"Sauvage F.","year":"2016","unstructured":"Sauvage F.; Barratt G.; Herfindal L.; Vergnaud-Gauduchon J.; The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status. Curr Pharm Biotechnol 2016,17(1),30-41","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fonc.2014.00101","volume":"4","author":"Basha R.","year":"2014","unstructured":"Basha R.; Sabnis N.; Heym K.; Bowman W.P.; Lacko A.G.; Targeted nanoparticles for pediatric leukemia therapy. Front Oncol 2014,4,101","journal-title":"Front Oncol"},{"key":"ref=19","first-page":"696","author":"Potocnic J.","year":"2011","unstructured":"Potocnic J.; Commision recommendation of 18 October 2011 on the definition of nanomaterial (2011\/696\/EU) Official Journal of the European Union. The European Union EU2011,696","journal-title":"The European Union"},{"key":"ref=20","first-page":"2486","volume":"47","author":"Wiernik P.H.","year":"1987","unstructured":"Wiernik P.H.; Schwartz E.L.; Strauman J.J.; Dutcher J.P.; Lipton R.B.; Paietta E.; Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987,47(9),2486-2493","journal-title":"Cancer Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"Weiss R.B.","year":"1990","unstructured":"Weiss R.B.; Donehower R.C.; Wiernik P.H.; Ohnuma T.; Gralla R.J.; Trump D.L.; Baker J.R.; Van Echo D.A.; Von Hoff D.D.; Leyland-Jones B.; Hypersensitivity reactions from taxol. J Clin Oncol 1990,8(7),1263-1268","journal-title":"J Clin Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"Gradishar W.J.","year":"2005","unstructured":"Gradishar W.J.; Tjulandin S.; Davidson N.; Shaw H.; Desai N.; Bhar P.; Hawkins M.; O\u2019Shaughnessy J.; Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005,23(31),7794-7803","journal-title":"J Clin Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/annonc\/mdj100","volume":"17","author":"Hennenfent K.L.","year":"2006","unstructured":"Hennenfent K.L.; Govindan R.; Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006,17(5),735-749","journal-title":"Ann Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.2147\/IJN.S132434","volume":"12","author":"Feng T.","year":"2017","unstructured":"Feng T.; Wei Y.; Lee R.J.; Zhao L.; Liposomal curcumin and its application in cancer. Int J Nanomedicine 2017,12,6027-6044","journal-title":"Int J Nanomedicine"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00216-010-3719-3","volume":"397","author":"Schiborr C.","year":"2010","unstructured":"Schiborr C.; Eckert G.P.; Rimbach G.; Frank J.; A validated method for the quantification of curcumin in plasma and brain tissue by fast narrow-bore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem 2010,397(5),1917-1925","journal-title":"Anal Bioanal Chem"},{"key":"ref=26","first-page":"486","volume":"27","author":"Pan M.H.","year":"1999","unstructured":"Pan M.H.; Huang T.M.; Lin J.K.; Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999,27(4),486-494","journal-title":"Drug Metab Dispos"},{"key":"ref=27","first-page":"1058","volume":"61","author":"Ireson C.","year":"2001","unstructured":"Ireson C.; Orr S.; Jones D.J.; Verschoyle R.; Lim C.K.; Luo J.L.; Howells L.; Plummer S.; Jukes R.; Williams M.; Steward W.P.; Gescher A.; Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001,61(3),1058-1064","journal-title":"Cancer Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.24336","volume":"125","author":"Narayanan N.K.","year":"2009","unstructured":"Narayanan N.K.; Nargi D.; Randolph C.; Narayanan B.A.; Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009,125(1),1-8","journal-title":"Int J Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5414\/CP202076","volume":"53","author":"Storka A.","year":"2015","unstructured":"Storka A.; Vcelar B.; Klickovic U.; Gouya G.; Weisshaar S.; Aschauer S.; Bolger G.; Helson L.; Wolzt M.; Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther 2015,53(1),54-65","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1023\/A:1008365716693","volume":"11","author":"Safra T.","year":"2000","unstructured":"Safra T.; Muggia F.; Jeffers S.; Tsao-Wei D.D.; Groshen S.; Lyass O.; Henderson R.; Berry G.; Gabizon A.; Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2. Ann Oncol 2000,11(8),1029-1033","journal-title":"Ann Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"O\u2019Brien M.E.","year":"2004","unstructured":"O\u2019Brien M.E.; Wigler N.; Inbar M.; Rosso R.; Grischke E.; Santoro A.; Catane R.; Kieback D.G.; Tomczak P.; Ackland S.P.; Orlandi F.; Mellars L.; Alland L.; Tendler C.; Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004,15(3),440-449","journal-title":"Ann Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1023\/A:1018907715905","volume":"10","author":"Gabizon A.A.","year":"1993","unstructured":"Gabizon A.A.; Barenholz Y.; Bialer M.; Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993,10(5),703-708","journal-title":"Pharm Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037:AID-CNCR13>3.0.CO;2-Z","volume":"89","author":"Lyass O.","year":"2000","unstructured":"Lyass O.; Uziely B.; Ben-Yosef R.; Tzemach D.; Heshing N.I.; Lotem M.; Brufman G.; Gabizon A.; Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000,89(5),1037-1047","journal-title":"Cancer"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.biopha.2017.09.059","volume":"95","author":"Shafei A.","year":"2017","unstructured":"Shafei A.; El-Bakly W.; Sobhy A.; Wagdy O.; Reda A.; Aboelenin O.; Marzouk A.; El Habak K.; Mostafa R.; Ali M.A.; Ellithy M.; A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother 2017,95,1209-1218","journal-title":"Biomed Pharmacother"},{"key":"ref=35","first-page":"6387","volume":"46","author":"Matsumura Y.","year":"1986","unstructured":"Matsumura Y.; Maeda H.; A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986,46(12 Pt 1),6387-6392","journal-title":"Cancer Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.addr.2017.07.007","volume":"119","author":"Ojha T.","year":"2017","unstructured":"Ojha T.; Pathak V.; Shi Y.; Hennink W.E.; Moonen C.T.W.; Storm G.; Kiessling F.; Lammers T.; Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv Drug Deliv Rev 2017,119,44-60","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3762\/bjnano.10.16","volume":"10","author":"Villaverde G.","year":"2019","unstructured":"Villaverde G.; Baeza A.; Targeting strategies for improving the efficacy of nanomedicine in oncology. Beilstein J Nanotechnol 2019,10,168-181","journal-title":"Beilstein J Nanotechnol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","volume":"13","author":"Mamot C.","year":"2012","unstructured":"Mamot C.; Ritschard R.; Wicki A.; Stehle G.; Dieterle T.; Bubendorf L.; Hilker C.; Deuster S.; Herrmann R.; Rochlitz C.; Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 2012,13(12),1234-1241","journal-title":"Lancet Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/smll.201001022","volume":"6","author":"Smith B.R.","year":"2010","unstructured":"Smith B.R.; Cheng Z.; De A.; Rosenberg J.; Gambhir S.S.; Dynamic visualization of RGD-quantum dot binding to tumor neovasculature and extravasation in multiple living mouse models using intravital microscopy. Small 2010,6(20),2222-2229","journal-title":"Small"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1046\/j.1525-1373.1999.d01-122.x","volume":"222","author":"Mizejewski G.J.","year":"1999","unstructured":"Mizejewski G.J.; Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999,222(2),124-138","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejpb.2014.04.002","volume":"88","author":"Myhren L.","year":"2014","unstructured":"Myhren L.; Nilssen I.M.; Nicolas V.; D\u00f8skeland S.O.; Barratt G.; Herfindal L.; Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia. Eur J Pharm Biopharm 2014,88(1),186-193","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1517\/17425247.5.3.309","volume":"5","author":"Zhao X.","year":"2008","unstructured":"Zhao X.; Li H.; Lee R.J.; Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008,5(3),309-319","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.pharmthera.2013.03.004","volume":"138","author":"Sapra P.","year":"2013","unstructured":"Sapra P.; Shor B.; Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther 2013,138(3),452-469","journal-title":"Pharmacol Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"Tsuchikama K.","year":"2018","unstructured":"Tsuchikama K.; An Z.; Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2018,9(1),33-46","journal-title":"Protein Cell"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.addr.2012.08.009","volume":"65","author":"Koshkaryev A.","year":"2013","unstructured":"Koshkaryev A.; Sawant R.; Deshpande M.; Torchilin V.; Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev 2013,65(1),24-35","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","volume":"14","author":"Sawant R.R.","year":"2012","unstructured":"Sawant R.R.; Torchilin V.P.; Challenges in development of targeted liposomal therapeutics. AAPS J 2012,14(2),303-315","journal-title":"AAPS J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3389\/fimmu.2017.01936","volume":"8","author":"Cuesta-Mateos C.","year":"2018","unstructured":"Cuesta-Mateos C.; Alcaraz-Serna A.; Somovilla-Crespo B.; Mu\u00f1oz-Calleja C.; Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets. Front Immunol 2018,8,1936","journal-title":"Front Immunol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fonc.2018.00152","volume":"8","author":"Sch\u00fcrch C.M.","year":"2018","unstructured":"Sch\u00fcrch C.M.; Therapeutic antibodies for myeloid neoplasms-current developments and future directions. Front Oncol 2018,8,152","journal-title":"Front Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"Cheever M.A.","year":"2009","unstructured":"Cheever M.A.; Allison J.P.; Ferris A.S.; Finn O.J.; Hastings B.M.; Hecht T.T.; Mellman I.; Prindiville S.A.; Viner J.L.; Weiner L.M.; Matrisian L.M.; The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009,15(17),5323-5337","journal-title":"Clin Cancer Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/leu.2012.145","volume":"26","author":"Anguille S.","year":"2012","unstructured":"Anguille S.; Van Tendeloo V.F.; Berneman Z.N.; Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012,26(10),2186-2196","journal-title":"Leukemia"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/10428190500301306","volume":"47","author":"Scholl S.","year":"2006","unstructured":"Scholl S.; Salzmann S.; Kaufmann A.M.; H\u00f6ffken K.; Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk Lymphoma 2006,47(2),307-312","journal-title":"Leuk Lymphoma"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3324\/haematol.2012.065581","volume":"97","author":"Snauwaert S.","year":"2012","unstructured":"Snauwaert S.; Vanhee S.; Goetgeluk G.; Verstichel G.; Van Caeneghem Y.; Velghe I.; Philipp\u00e9 J.; Berneman Z.N.; Plum J.; Taghon T.; Leclercq G.; Thielemans K.; Kerre T.; Vandekerckhove B.; RHAMM\/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica 2012,97(10),1539-1547","journal-title":"Haematologica"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"Jin L.","year":"2006","unstructured":"Jin L.; Hope K.J.; Zhai Q.; Smadja-Joffe F.; Dick J.E.; Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006,12(10),1167-1174","journal-title":"Nat Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/asheducation-2015.1.584","volume":"2015","author":"Buckley S.A.","year":"2015","unstructured":"Buckley S.A.; Walter R.B.; Antigen-specific immunotherapies for acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2015,2015,584-595","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/B978-0-12-385493-3.00010-3","volume":"103","author":"Gorczyca W.","year":"2011","unstructured":"Gorczyca W.; Sun Z.Y.; Cronin W.; Li X.; Mau S.; Tugulea S.; Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol 2011,103,221-266","journal-title":"Methods Cell Biol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1758834015615514","volume":"8","author":"Wurz G.T.","year":"2016","unstructured":"Wurz G.T.; Kao C.J.; DeGregorio M.W.; Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016,8(1),4","journal-title":"Ther Adv Med Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1128\/MCB.00352-17","volume":"37","author":"Zaidi S.K.","year":"2017","unstructured":"Zaidi S.K.; Frietze S.E.; Gordon J.A.; Heath J.L.; Messier T.; Hong D.; Boyd J.R.; Kang M.; Imbalzano A.N.; Lian J.B.; Stein J.L.; Stein G.S.; Bivalent Epigenetic Control of Oncofetal Gene Expression in Cancer. Mol Cell Biol 2017,37(23),37","journal-title":"Mol Cell Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2018.08.006","volume":"53","author":"Gordeeva O.","year":"2018","unstructured":"Gordeeva O.; Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy. Semin Cancer Biol 2018,53,75-89","journal-title":"Semin Cancer Biol"},{"key":"ref=59","first-page":"73","volume":"9","author":"Ding K.","year":"2012","unstructured":"Ding K.; Wang X.M.; Fu R.; Ruan E.B.; Liu H.; Shao Z.H.; PRAME gene expression in acute leukemia and its clinical significance. Cancer Biol Med 2012,9(1),73-76","journal-title":"Cancer Biol Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1389450116666150223120005","volume":"18","author":"Goswami M.","year":"2017","unstructured":"Goswami M.; Hourigan C.S.; Novel antigen targets for immunotherapy of acute myeloid leukemia. Curr Drug Targets 2017,18(3),296-303","journal-title":"Curr Drug Targets"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/leu.2017.259","volume":"32","author":"Kumar B.","year":"2018","unstructured":"Kumar B.; Garcia M.; Weng L.; Jung X.; Murakami J.L.; Hu X.; McDonald T.; Lin A.; Kumar A.R.; DiGiusto D.L.; Stein A.S.; Pullarkat V.A.; Hui S.K.; Carlesso N.; Kuo Y.H.; Bhatia R.; Marcucci G.; Chen C.C.; Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 2018,32(3),575-587","journal-title":"Leukemia"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbamcr.2015.08.003","volume":"1863","author":"Bakker E.","year":"2016","unstructured":"Bakker E.; Qattan M.; Mutti L.; Demonacos C.; Krstic-Demonacos M.; The role of microenvironment and immunity in drug response in leukemia. Biochim Biophys Acta 2016,1863(3),414-426","journal-title":"Biochim Biophys Acta"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nbt.1607","volume":"28","author":"Saito Y.","year":"2010","unstructured":"Saito Y.; Uchida N.; Tanaka S.; Suzuki N.; Tomizawa-Murasawa M.; Sone A.; Najima Y.; Takagi S.; Aoki Y.; Wake A.; Taniguchi S.; Shultz L.D.; Ishikawa F.; Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010,28(3),275-280","journal-title":"Nat Biotechnol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","volume":"29","author":"Konopleva M.Y.","year":"2011","unstructured":"Konopleva M.Y.; Jordan C.T.; Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011,29(5),591-599","journal-title":"J Clin Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","volume":"368","author":"Hui L.","year":"2015","unstructured":"Hui L.; Chen Y.; Tumor microenvironment: Sanctuary of the devil. Cancer Lett 2015,368(1),7-13","journal-title":"Cancer Lett"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","volume":"12","author":"Konopleva M.","year":"2009","unstructured":"Konopleva M.; Tabe Y.; Zeng Z.; Andreeff M.; Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009,12(4-5),103-113","journal-title":"Drug Resist Updat"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/156652412798376125","volume":"12","author":"Aggarwal R.","year":"2012","unstructured":"Aggarwal R.; Lu J.; Pompili V.J.; Das H.; Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application. Curr Mol Med 2012,12(1),34-49","journal-title":"Curr Mol Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2013.085209","volume":"99","author":"Pollyea D.A.","year":"2014","unstructured":"Pollyea D.A.; Gutman J.A.; Gore L.; Smith C.A.; Jordan C.T.; Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica 2014,99(8),1277-1284","journal-title":"Haematologica"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2007.09.003","volume":"151","author":"Colmone A.","year":"2008","unstructured":"Colmone A.; Sipkins D.A.; Beyond angiogenesis: the role of endothelium in the bone marrow vascular niche. Transl Res 2008,151(1),1-9","journal-title":"Transl Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s12185-017-2221-5","volume":"105","author":"Hanekamp D.","year":"2017","unstructured":"Hanekamp D.; Cloos J.; Schuurhuis G.J.; Leukemic stem cells: identification and clinical application. Int J Hematol 2017,105(5),549-557","journal-title":"Int J Hematol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ijpharm.2017.06.003","volume":"529","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Liu F.; Wang Q.; Xiang H.; Jin H.; Li H.; Mao S.; A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells. Int J Pharm 2017,529(1-2),531-542","journal-title":"Int J Pharm"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1080\/10717544.2017.1367976","volume":"24","author":"Wu H.","year":"2017","unstructured":"Wu H.; Wang M.; Dai B.; Zhang Y.; Yang Y.; Li Q.; Duan M.; Zhang X.; Wang X.; Li A.; Zhang L.; Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics. Drug Deliv 2017,24(1),1216-1229","journal-title":"Drug Deliv"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/blood-2016-09-740654","volume":"129","author":"Knapp D.J.","year":"2017","unstructured":"Knapp D.J.; Hammond C.A.; Aghaeepour N.; Miller P.H.; Pellacani D.; Beer P.A.; Sachs K.; Qiao W.; Wang W.; Humphries R.K.; Sauvageau G.; Zandstra P.W.; Bendall S.C.; Nolan G.P.; Hansen C.; Eaves C.J.; Distinct signaling programs control human hematopoietic stem cell survival and proliferation. Blood 2017,129(3),307-318","journal-title":"Blood"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cam4.203","volume":"3","author":"Favreau A.J.","year":"2014","unstructured":"Favreau A.J.; Vary C.P.; Brooks P.C.; Sathyanarayana P.; Cryptic collagen IV promotes cell migration and adhesion in myeloid leukemia. Cancer Med 2014,3(2),265-272","journal-title":"Cancer Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12015-015-9639-z","volume":"12","author":"Le Y.","year":"2016","unstructured":"Le Y.; Fraineau S.; Chandran P.; Sabloff M.; Brand M.; Lavoie J.R.; Gagne R.; Rosu-Myles M.; Yauk C.L.; Richardson R.B.; Allan D.S.; Adipogenic mesenchymal stromal cells from bone marrow and their hematopoietic supportive role: towards understanding the permissive marrow microenvironment in acute myeloid leukemia. Stem Cell Rev 2016,12(2),235-244","journal-title":"Stem Cell Rev"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.scr.2015.09.008","volume":"15","author":"Reikvam H.","year":"2015","unstructured":"Reikvam H.; Brenner A.K.; Hagen K.M.; Liseth K.; Skrede S.; Hatfield K.J.; Bruserud \u00d8.; The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res (Amst) 2015,15(3),530-541","journal-title":"Stem Cell Res (Amst)"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood-2012-06-437988","volume":"122","author":"Battula V.L.","year":"2013","unstructured":"Battula V.L.; Chen Y.; Cabreira, Mda.G.; Ruvolo, V.; Wang, Z.; Ma, W.; Konoplev, S.; Shpall, E.; Lyons, K.; Strunk, D.; Bueso-Ramos, C.; Davis, R.E.; Konopleva, M.; Andreeff, M. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood 2013,122(3),357-366","journal-title":"Blood"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/jmri.23619","volume":"36","author":"Griffith J.F.","year":"2012","unstructured":"Griffith J.F.; Yeung D.K.; Ma H.T.; Leung J.C.; Kwok T.C.; Leung P.C.; Bone marrow fat content in the elderly: a reversal of sex difference seen in younger subjects. J Magn Reson Imaging 2012,36(1),225-230","journal-title":"J Magn Reson Imaging"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","volume":"129","author":"Korn C.","year":"2017","unstructured":"Korn C.; M\u00e9ndez-Ferrer S.; Myeloid malignancies and the microenvironment. Blood 2017,129(7),811-822","journal-title":"Blood"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41598-017-00685-9","volume":"7","author":"Yamamoto H.","year":"2017","unstructured":"Yamamoto H.; Takada T.; Yamanashi Y.; Ogura M.; Masuo Y.; Harada-Shiba M.; Suzuki H.; VLDL\/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body. Sci Rep 2017,7(1),633","journal-title":"Sci Rep"},{"key":"ref=81","first-page":"199","volume":"53","author":"Sobansky M.R.","year":"2012","unstructured":"Sobansky M.R.; Hage D.S.; Analysis of drug interactions with lipoproteins by high-performance affinity chromatography. Adv Med Biol 2012,53,199-216","journal-title":"Adv Med Biol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nrd2353","volume":"7","author":"Wasan K.M.","year":"2008","unstructured":"Wasan K.M.; Brocks D.R.; Lee S.D.; Sachs-Barrable K.; Thornton S.J.; Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 2008,7(1),84-99","journal-title":"Nat Rev Drug Discov"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/79561","author":"Shi G.","year":"2018","unstructured":"Shi G.; Li J.; Yan X.; Jin K.; Li W.; Liu X.; Zhao J.; Shang W.; Zhang R.; Low-density lipoprotein-decorated and Adriamycin-loaded silica nanoparticles for tumor-targeted chemotherapy of colorectal cancer. Adv Clin Exp Med 2018","journal-title":"Adv Clin Exp Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.apsb.2017.11.006","volume":"8","author":"Ma X.","year":"2018","unstructured":"Ma X.; Song Q.; Gao X.; Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery. Acta Pharm Sin B 2018,8(1),51-63","journal-title":"Acta Pharm Sin B"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bbamcr.2015.07.008","volume":"1863","author":"Yan M.","year":"2016","unstructured":"Yan M.; Jurasz P.; The role of platelets in the tumor microenvironment: From solid tumors to leukemia. Biochim Biophys Acta 2016,1863(3),392-400","journal-title":"Biochim Biophys Acta"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13402-011-0017-9","volume":"34","author":"Weidenaar A.C.","year":"2011","unstructured":"Weidenaar A.C.; ter Elst A.; Koopmans-Klein G.; Rosati S.; den Dunnen W.F.; Meeuwsen-de Boer T.; Kamps W.A.; Vellenga E.; de Bont E.S.; High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow. Cell Oncol (Dordr) 2011,34(4),289-296","journal-title":"Cell Oncol (Dordr)"},{"key":"ref=87","first-page":"321","volume":"1836","author":"Barcellos-de-Souza P.","year":"2013","unstructured":"Barcellos-de-Souza P.; Gori V.; Bambi F.; Chiarugi P.; Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta 2013,1836(2),321-335","journal-title":"Biochim Biophys Acta"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/128608","volume":"2012","author":"Trujillo A.","year":"2012","unstructured":"Trujillo A.; McGee C.; Cogle C.R.; Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012,2012","journal-title":"J Oncol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.exphem.2016.01.008","volume":"44","author":"Pizzo R.J.","year":"2016","unstructured":"Pizzo R.J.; Azadniv M.; Guo N.; Acklin J.; Lacagnina K.; Coppage M.; Liesveld J.L.; Phenotypic, genotypic, and functional characterization of normal and acute myeloid leukemia-derived marrow endothelial cells. Exp Hematol 2016,44(5),378-389","journal-title":"Exp Hematol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1684\/ecn.2012.0322","volume":"23","author":"Reikvam H.","year":"2012","unstructured":"Reikvam H.; Hatfield K.J.; Fredly H.; Nepstad I.; Mosevoll K.A.; Bruserud \u00d8.; The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw 2012,23(4),140-153","journal-title":"Eur Cytokine Netw"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/leu.2014.109","volume":"28","author":"Cogle C.R.","year":"2014","unstructured":"Cogle C.R.; Goldman D.C.; Madlambayan G.J.; Leon R.P.; Masri A.A.; Clark H.A.; Asbaghi S.A.; Tyner J.W.; Dunlap J.; Fan G.; Kovacsovics T.; Liu Q.; Meacham A.; Hamlin K.L.; Hromas R.A.; Scott E.W.; Fleming W.H.; Functional integration of acute myeloid leukemia into the vascular niche. Leukemia 2014,28(10),1978-1987","journal-title":"Leukemia"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.canlet.2015.05.007","volume":"380","author":"Cogle C.R.","year":"2016","unstructured":"Cogle C.R.; Bosse R.C.; Brewer T.; Migdady Y.; Shirzad R.; Kampen K.R.; Saki N.; Acute myeloid leukemia in the vascular niche. Cancer Lett 2016,380(2),552-560","journal-title":"Cancer Lett"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1039\/C5CS00499C","volume":"44","author":"Setyawati M.I.","year":"2015","unstructured":"Setyawati M.I.; Tay C.Y.; Docter D.; Stauber R.H.; Leong D.T.; Understanding and exploiting nanoparticles\u2019 intimacy with the blood vessel and blood. Chem Soc Rev 2015,44(22),8174-8199","journal-title":"Chem Soc Rev"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/BF00691283","volume":"78","author":"Shibata S.","year":"1989","unstructured":"Shibata S.; Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol 1989,78(6),561-571","journal-title":"Acta Neuropathol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1006\/mvre.1999.2188","volume":"58","author":"Schlageter K.E.","year":"1999","unstructured":"Schlageter K.E.; Molnar P.; Lapin G.D.; Groothuis D.R.; Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999,58(3),312-328","journal-title":"Microvasc Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1006\/mvre.1999.2207","volume":"59","author":"Feng D.","year":"2000","unstructured":"Feng D.; Nagy J.A.; Dvorak A.M.; Dvorak H.F.; Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res 2000,59(1),24-37","journal-title":"Microvasc Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0378-5173(02)00703-2","volume":"253","author":"Awasthi V.D.","year":"2003","unstructured":"Awasthi V.D.; Garcia D.; Goins B.A.; Phillips W.T.; Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm 2003,253(1-2),121-132","journal-title":"Int J Pharm"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"34","DOI":"10.21037\/sci.2018.09.05","volume":"5","author":"Kumar B.","year":"2018","unstructured":"Kumar B.; Chen C.C.; Acute myeloid leukemia remodels endosteal vascular niche into a leukemic niche. Stem Cell Investig 2018,5,34","journal-title":"Stem Cell Investig"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.stem.2017.11.006","volume":"22","author":"Duarte D.","year":"2018","unstructured":"Duarte D.; Hawkins E.D.; Akinduro O.; Ang H.; De Filippo K.; Kong I.Y.; Haltalli M.; Ruivo N.; Straszkowski L.; Vervoort S.J.; McLean C.; Weber T.S.; Khorshed R.; Pirillo C.; Wei A.; Ramasamy S.K.; Kusumbe A.P.; Duffy K.; Adams R.H.; Purton L.E.; Carlin L.M.; Lo Celso C.; Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 2018,22,64-77","journal-title":"Cell Stem Cell"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/carcin\/bgs386","volume":"34","author":"Zhang J.","year":"2013","unstructured":"Zhang J.; Ye J.; Ma D.; Liu N.; Wu H.; Yu S.; Sun X.; Tse W.; Ji C.; Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch\/Dll4 pathway. Carcinogenesis 2013,34(3),667-677","journal-title":"Carcinogenesis"},{"key":"ref=101","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.14050","volume":"144","author":"Medinger M.","year":"2014","unstructured":"Medinger M.; Passweg J.; Role of tumour angiogenesis in haematological malignancies. Swiss Med Wkly 2014,144","journal-title":"Swiss Med Wkly"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","volume":"65","author":"Markman J.L.","year":"2013","unstructured":"Markman J.L.; Rekechenetskiy A.; Holler E.; Ljubimova J.Y.; Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013,65(13-14),1866-1879","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1586\/14737140.2015.1086647","volume":"15","author":"Alphand\u00e9ry E.","year":"2015","unstructured":"Alphand\u00e9ry E.; Grand-Dewyse P.; Lef\u00e8vre R.; Mandawala C.; Durand-Dubief M.; Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther 2015,15(10),1233-1255","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.colsurfb.2017.07.085","volume":"159","author":"Eloy J.O.","year":"2017","unstructured":"Eloy J.O.; Petrilli R.; Trevizan L.N.F.; Chorilli M.; Immunoliposomes: A review on functionalization strategies and targets for drug delivery. Colloids Surf B Biointerfaces 2017,159,454-467","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1081\/LPR-120004771","volume":"12","author":"Allen T.M.","year":"2002","unstructured":"Allen T.M.; Sapra P.; Moase E.; Moreira J.; Iden D.; Adventures in targeting. J Liposome Res 2002,12(1-2),5-12","journal-title":"J Liposome Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0014-5793(97)00905-8","volume":"413","author":"Maruyama K.","year":"1997","unstructured":"Maruyama K.; Takahashi N.; Tagawa T.; Nagaike K.; Iwatsuru M.; Immunoliposomes bearing polyethyleneglycol-coupled Fab\u2019 fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997,413(1),177-180","journal-title":"FEBS Lett"},{"key":"ref=107","first-page":"6942","volume":"60","author":"Sugano M.","year":"2000","unstructured":"Sugano M.; Egilmez N.K.; Yokota S.J.; Chen F.A.; Harding J.; Huang S.K.; Bankert R.B.; Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000,60(24),6942-6949","journal-title":"Cancer Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0304-3835(03)00099-5","volume":"197","author":"Brignole C.","year":"2003","unstructured":"Brignole C.; Marimpietri D.; Gambini C.; Allen T.M.; Ponzoni M.; Pastorino F.; Development of Fab\u2019 fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett 2003,197(1-2),199-204","journal-title":"Cancer Lett"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/molecules23040907","volume":"23","author":"Olusanya T.O.B.","year":"2018","unstructured":"Olusanya T.O.B.; Haj Ahmad R.R.; Ibegbu D.M.; Smith J.R.; Elkordy A.A.; Liposomal drug delivery systems and anticancer drugs. Molecules 2018,23(4),23","journal-title":"Molecules"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-4939-7142-8_5","volume":"1633","author":"Zeng Z.","year":"2017","unstructured":"Zeng Z.; Konopleva M.; Andreeff M.; Single-cell mass cytometry of acute myeloid leukemia and leukemia stem\/progenitor cells. Methods Mol Biol 2017,1633,75-86","journal-title":"Methods Mol Biol"},{"key":"ref=111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153207","volume":"11","author":"Ferrell P.B.","year":"2016","unstructured":"Ferrell P.B.; Diggins K.E.; Polikowsky H.G.; Mohan S.R.; Seegmiller A.C.; Irish J.M.; High-dimensional analysis of acute myeloid leukemia reveals phenotypic changes in persistent cells during induction therapy. PLoS One 2016,11(4)","journal-title":"PLoS One"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMp1006304","volume":"363","author":"Hamburg M.A.","year":"2010","unstructured":"Hamburg M.A.; Collins F.S.; The path to personalized medicine. N Engl J Med 2010,363(4),301-304","journal-title":"N Engl J Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nbt0817-797c","volume":"35","author":"Schellekens H.","year":"2017","unstructured":"Schellekens H.; Aldosari M.; Talsma H.; Mastrobattista E.; Erratum: Making individualized drugs a reality. Nat Biotechnol 2017,35(8),797","journal-title":"Nat Biotechnol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nbt.3888","volume":"35","author":"Schellekens H.","year":"2017","unstructured":"Schellekens H.; Aldosari M.; Talsma H.; Mastrobattista E.; Making individualized drugs a reality. Nat Biotechnol 2017,35(6),507-513","journal-title":"Nat Biotechnol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.beha.2013.10.002","volume":"26","author":"Rowe J.M.","year":"2013","unstructured":"Rowe J.M.; Important milestones in acute leukemia in 2013. Best Pract Res Clin Haematol 2013,26(3),241-244","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40291-018-0338-8","volume":"22","author":"Liu F.","year":"2018","unstructured":"Liu F.; Wang C.; Gao Y.; Li X.; Tian F.; Zhang Y.; Fu M.; Li P.; Wang Y.; Wang F.; Current transport systems and clinical applications for small interfering RNA (siRNA) drugs. Mol Diagn Ther 2018,22(5),551-569","journal-title":"Mol Diagn Ther"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.2174\/138161282131151013185850","volume":"21","author":"Vhora I.","year":"2015","unstructured":"Vhora I.; Patil S.; Amrutiya J.; Misra A.; Liposomes and Lipid Envelope-Type Systems for Systemic siRNA Delivery. Curr Pharm Des 2015,21(31),4541-4555","journal-title":"Curr Pharm Des"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T08:03:49Z","timestamp":1607846629000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172181\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":117,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2019,10,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190517114450","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}